Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Feb-24 7:20 PM View:  | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 16-Feb-24 | Sale (Planned) | 6,812 | $10.02 | $68,222.90 | (9%) 75.14K to 68.33K | |
| 30-Jan-24 6:52 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Sale | 2,334 | $7.99 | $18,649.10 | (6%) 38.74K to 36.4K | |
| 30-Jan-24 6:52 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Exercise | 3,924 | -- | -- | 26% 15.26K to 19.19K | |
| 30-Jan-24 6:53 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Exercise | 4,886 | -- | -- | 7% 71.93K to 76.82K | |
| 30-Jan-24 6:52 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Sale | 1,760 | $7.99 | $14,062.80 | (9%) 19.19K to 17.43K | |
| 30-Jan-24 6:52 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Exercise | 5,207 | -- | -- | 16% 33.53K to 38.74K | |
| 30-Jan-24 6:53 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Sale | 1,671 | $7.99 | $13,351.60 | (2%) 76.82K to 75.14K | |
| 21-Dec-23 5:19 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 20-Dec-23 | Sale (Planned) | 3,541 | $10.00 | $35,421.00 | (5%) 75.47K to 71.93K | |
| 20-Dec-23 4:55 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 19-Dec-23 | Sale (Planned) | 10,906 | $10.00 | $109,093.00 | (13%) 86.38K to 75.47K | |
| 01-Nov-23 4:40 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-23 | Option Sale | 1,633 | $5.20 | $8,487.35 | (5%) 35.16K to 33.53K | |
| 01-Nov-23 4:41 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-23 | Option Sale | 1,080 | $5.20 | $5,613.19 | (1%) 87.46K to 86.38K | |
| 01-Nov-23 4:40 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-23 | Option Sale | 1,232 | $5.20 | $6,403.20 | (7%) 16.5K to 15.26K | |
| 01-Nov-23 4:40 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-23 | Option Exercise | 5,207 | -- | -- | 17% 29.95K to 35.16K | |
| 01-Nov-23 4:41 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-23 | Option Exercise | 4,886 | -- | -- | 6% 82.57K to 87.46K | |
| 01-Nov-23 4:40 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-23 | Option Exercise | 3,924 | -- | -- | 31% 12.57K to 16.5K | |
| 01-Aug-23 4:27 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 31-Jul-23 | Option Sale | 1,420 | $9.65 | $13,709.70 | (10%) 13.96K to 12.54K | |
| 01-Aug-23 4:26 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Jul-23 | Option Sale | 1,884 | $9.65 | $18,189.50 | (6%) 31.84K to 29.95K | |
| 01-Aug-23 4:28 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Jul-23 | Option Sale | 1,245 | $9.65 | $12,020.10 | (1%) 83.82K to 82.57K | |
| 01-Aug-23 4:27 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-23 | Option Exercise | 3,924 | -- | -- | 39% 10.04K to 13.96K | |
| 01-Aug-23 4:26 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-23 | Option Exercise | 5,207 | -- | -- | 20% 26.63K to 31.84K | |
| 01-Aug-23 4:28 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-23 | Option Exercise | 4,886 | -- | -- | 6% 78.93K to 83.82K | |
| 02-May-23 10:00 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 01-May-23 | Option Sale | 342 | $9.88 | $3,377.69 | (5%) 6.46K to 6.11K | |
| 02-May-23 10:00 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 01-May-23 | Option Sale | 682 | $9.88 | $6,735.64 | (6%) 10.72K to 10.04K | |
| 02-May-23 10:00 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 01-May-23 | Option Sale | 1,136 | $9.88 | $11,219.50 | (4%) 27.77K to 26.63K | |
| 02-May-23 10:00 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 01-May-23 | Option Sale | 721 | $9.88 | $7,120.81 | (< 1%) 79.65K to 78.93K | |
| 02-May-23 10:00 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-23 | Option Exercise | 1,924 | -- | -- | 22% 8.8K to 10.72K | |
| 02-May-23 10:00 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-23 | Option Exercise | 3,206 | -- | -- | 13% 24.56K to 27.77K | |
| 02-May-23 10:00 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-23 | Option Exercise | 2,886 | -- | -- | 4% 76.77K to 79.65K | |
| 02-May-23 10:00 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-23 | Option Exercise | 962 | -- | -- | 18% 5.49K to 6.46K | |
| 01-Feb-23 4:17 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Exercise | 2,886 | -- | -- | 4% 74.8K to 77.69K | |
| 01-Feb-23 4:18 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Exercise | 962 | -- | -- | 28% 3.4K to 4.36K | |
| 01-Feb-23 4:16 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Sale | 848 | $11.78 | $9,989.10 | (10%) 8.11K to 7.26K | |
| 01-Feb-23 4:15 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Sale | 1,412 | $11.78 | $16,632.80 | (6%) 24.42K to 23.01K | |
| 01-Feb-23 4:17 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Sale | 924 | $11.78 | $10,884.40 | (1%) 77.69K to 76.77K | |
| 01-Feb-23 4:18 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Sale | 424 | $11.78 | $4,994.55 | (10%) 4.36K to 3.94K | |
| 01-Feb-23 4:16 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Exercise | 1,924 | -- | -- | 31% 6.18K to 8.11K | |
| 01-Feb-23 4:15 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-23 | Option Exercise | 3,207 | -- | -- | 15% 21.21K to 24.42K | |
| 01-Nov-22 7:33 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-22 | Option Sale | 1,165 | $12.88 | $15,005.80 | (5%) 22.38K to 21.21K | |
| 01-Nov-22 7:35 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-22 | Option Sale | 739 | $12.88 | $9,518.69 | (< 1%) 75.54K to 74.8K | |
| 01-Nov-22 7:32 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-22 | Option Sale | 350 | $12.88 | $4,508.17 | (9%) 3.75K to 3.4K | |
| 01-Nov-22 7:34 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-22 | Option Sale | 699 | $12.88 | $9,003.47 | (10%) 6.88K to 6.18K | |
| 01-Nov-22 7:34 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-22 | Option Exercise | 1,924 | -- | -- | 39% 4.96K to 6.88K | |
| 01-Nov-22 7:33 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-22 | Option Exercise | 3,207 | -- | -- | 17% 19.17K to 22.38K | |
| 01-Nov-22 7:35 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-22 | Option Exercise | 2,886 | -- | -- | 4% 72.66K to 75.54K | |
| 01-Nov-22 7:32 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-22 | Option Exercise | 962 | -- | -- | 34% 2.79K to 3.75K | |
| 02-Aug-22 5:50 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-22 | Option Sale | 712 | $15.67 | $11,157.00 | (13%) 5.33K to 4.62K | |
| 02-Aug-22 5:45 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-22 | Option Sale | 1,186 | $15.67 | $18,584.60 | (6%) 20.36K to 19.17K | |
| 02-Aug-22 5:46 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-22 | Option Sale | 752 | $15.67 | $11,783.80 | (1%) 73.41K to 72.66K | |
| 02-Aug-22 5:48 PM View: | Wolff Stefani EVP and COO | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-22 | Option Sale | 356 | $15.67 | $5,578.52 | (22%) 1.59K to 1.24K | |
| 02-Aug-22 5:50 PM View: | Ring Christine General Counsel | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-22 | Option Exercise | 1,924 | -- | -- | 57% 3.4K to 5.33K |
